OPEN ACCESS
©NIJPP
Publications 2024
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY (NIJPP)

Volume 5 Issue 3 2024

https://doi.org/10.59298/NIJPP/2024/5333370

Extracellular Vesicles as Novel Immunomodulatory Agents: Potential for Autoimmune and Inflammatory Diseases

Awafung Emmanuel Adie[1]

[1]**Department of Biomedical Engineering Kampala International University Uganda**
Email: awafungadie@gmail.com; awafungadie@kiu.ac.ug

ABSTRACT

Extracellular vesicles (EVs) are nanoscale membrane-bound particles released by various cell types, including immune and non-immune cells, and play crucial roles in intercellular communication. Emerging evidence suggests that EVs have significant immunomodulatory properties, influencing various aspects of immune responses and contributing to the pathogenesis of autoimmune and inflammatory diseases. This review explores the biogenesis, composition, and functional roles of EVs, focusing on their potential as novel immunomodulatory agents. We discuss how EVs can modulate immune cell activation, differentiation, and function, highlighting their roles in promoting immune tolerance and regulating inflammatory processes. Furthermore, we explore the therapeutic applications of EVs in managing autoimmune and inflammatory diseases, including their potential as biomarkers, drug delivery vehicles, and therapeutic agents. We also address the challenges and limitations associated with EV research, including isolation techniques, standardization, and the need for a better understanding of their mechanisms of action. This review emphasizes the potential of EVs as innovative therapeutic strategies for treating autoimmune and inflammatory conditions, paving the way for future research to harness their immunomodulatory capabilities.

Keywords: Extracellular vesicles, Immunomodulation, Autoimmune diseases, Inflammatory diseases, Intercellular communication

INTRODUCTION

Extracellular vesicles (EVs) are nanoscale membrane-bound particles released by virtually all cell types into the extracellular environment [1]. They play a vital role in intercellular communication and are involved in various physiological and pathological processes. EVs can be categorized into three main types: exosomes (30-150 nm in diameter), microvesicles (100-1000 nm), and apoptotic bodies (larger than 1 μm). The biogenesis of EVs involves complex cellular processes, including membrane budding, invagination, and fusion [2, 3]. Exosomes are formed through the endosomal pathway, while microvesicles originate from direct outward budding of the plasma membrane. Apoptotic bodies, as their name suggests, are generated during programmed cell death and can encapsulate cellular components. One of the most intriguing aspects of EVs is their composition, which is enriched in various bioactive molecules, including proteins, lipids, mRNA, and microRNA [4]. This diverse cargo allows EVs to transfer molecular signals to recipient cells, influencing their behavior and function. The capacity of EVs to carry and deliver bioactive molecules effectively positions them as crucial players in modulating immune responses, particularly in the context of autoimmune and inflammatory diseases [5]. The immune system relies on a delicate balance between activation and regulation to maintain homeostasis and prevent autoimmune reactions. Dysregulation of this balance can lead to the development of autoimmune disorders, where the immune system mistakenly targets the body's own tissues. Recent studies have highlighted the role of EVs in promoting immune tolerance and regulating inflammation. For instance, EVs derived from regulatory T cells and mesenchymal stem cells (MSCs) contain immunosuppressive molecules that can inhibit effector T cell activation and promote a tolerogenic environment [6, 7]. Conversely, EVs released during inflammatory conditions can carry pro-inflammatory signals that amplify immune responses and contribute to tissue damage [8].

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

The potential of EVs as novel immunomodulatory agents has garnered significant attention in recent years. Their ability to modulate various aspects of the immune response makes them promising candidates for therapeutic applications in autoimmune and inflammatory diseases. EVs can serve as biomarkers for disease diagnosis and progression, and their natural ability to deliver bioactive molecules positions them as effective drug delivery vehicles [9]. Furthermore, MSC-derived EVs have shown particular promise in clinical settings due to their ability to induce immunomodulation and promote tissue repair [10]. As research into EVs continues to evolve, it is essential to address the challenges associated with their isolation, characterization, and mechanistic understanding. Standardization of EV isolation protocols and a comprehensive exploration of their mechanisms of action will pave the way for innovative therapeutic strategies harnessing the immunomodulatory capabilities of EVs, ultimately offering new hope for patients suffering from autoimmune and inflammatory diseases.

Biogenesis and Composition of Extracellular Vesicles

Biogenesis

The formation of EVs is a complex process that involves several stages, including membrane budding, invagination, and fusion [11]. For exosomes, inward budding of the plasma membrane forms early endosomes, which mature into late endosomes. During this process, small intraluminal vesicles (ILVs) are generated, which accumulate within the late endosomes and eventually become exosomes. Upon fusion of the late endosomes with the plasma membrane, exosomes are released into the extracellular space. Microvesicles, on the other hand, are formed by direct outward budding from the plasma membrane, a process that involves cytoskeletal rearrangements and membrane asymmetry [12]. Apoptotic bodies are generated during cell death, encapsulating cellular components and cytoplasmic materials.

Composition

The composition of EVs is highly variable and depends on the cell type, physiological conditions, and environmental factors. EVs are enriched in a variety of bioactive molecules, including:

- **Proteins:** EVs contain surface proteins that facilitate interactions with recipient cells and proteins involved in various signaling pathways, including tetraspanins (e.g., CD63, CD81), heat shock proteins, and membrane-associated proteins.
- **Lipids:** The lipid composition of EVs is distinct from that of the parent cell membrane, often enriched in sphingolipids, cholesterol, and phosphatidylserine, which influence membrane fluidity and signaling.
- **Nucleic Acids:** EVs carry various forms of RNA, including mRNA and non-coding RNAs such as microRNA (miRNA), which can be transferred to recipient cells and modulate gene expression.

This diverse composition allows EVs to influence a range of biological processes, including immune modulation, inflammation, and tissue repair [13].

Role of Extracellular Vesicles in Immunomodulation

Modulation of Immune Cell Activation

EVs can modulate the activation and function of various immune cells, including T cells, B cells, dendritic cells (DCs), and macrophages. For example, EVs derived from activated immune cells can enhance the activation and proliferation of T cells by delivering antigenic material and co-stimulatory signals [14]. Conversely, EVs can also promote immune tolerance. Regulatory T cell-derived EVs, for instance, contain immunosuppressive molecules such as transforming growth factor-beta (TGF-β) and indoleamine 2, 3-dioxygenase (IDO), which can inhibit the activation of effector T cells and promote regulatory pathways [15].

Regulation of Inflammation

EVs are also involved in the regulation of inflammatory processes. Inflammatory cytokines can induce the release of EVs from various cell types, including macrophages and epithelial cells [16]. These EVs can carry pro-inflammatory signals, such as cytokines and chemokines, contributing to the amplification of the inflammatory response. On the other hand, EVs can also contain anti-inflammatory mediators that help resolve inflammation and restore homeostasis [17]. For instance, EVs from mesenchymal stem cells (MSCs) have been shown to possess anti-inflammatory properties, promoting tissue repair and regeneration [18].

Interplay with the Immune System

The interaction of EVs with the immune system is complex and context-dependent. Depending on their origin and composition, EVs can either enhance or suppress immune responses. The dual role of EVs in promoting immune tolerance and inflammation is particularly relevant in the context of autoimmune diseases and chronic inflammatory conditions [19]. Understanding these interactions is crucial for developing therapeutic strategies that leverage EVs for immunomodulation.

Therapeutic Potential of Extracellular Vesicles

Biomarkers for Autoimmune and Inflammatory Diseases

EVs have shown potential as novel biomarkers for autoimmune and inflammatory diseases. Their cargo reflects the physiological state of the parent cell, making them suitable for non-invasive diagnostics. For example, specific

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

miRNA profiles in EVs have been associated with diseases such as rheumatoid arthritis and systemic lupus erythematosus, providing insights into disease mechanisms and progression [20].

Drug Delivery Vehicles

Due to their natural ability to deliver bioactive molecules, EVs are being explored as drug delivery vehicles. EVs can encapsulate therapeutic agents, including small molecules, RNA, and proteins, and deliver them to target cells with minimal toxicity [21, 22]. This approach enhances the efficacy of therapeutics while reducing side effects, making EVs attractive candidates for targeted therapy in autoimmune and inflammatory diseases.

Therapeutic Agents

EVs can also be used as therapeutic agents themselves. For instance, MSC-derived EVs have demonstrated immunomodulatory effects, promoting tissue repair and modulating immune responses in preclinical models of autoimmune diseases [23]. This ability to induce immune tolerance and regulate inflammation positions EVs as a promising therapeutic strategy for treating autoimmune and inflammatory conditions [24].

Challenges and Limitations

Despite the promising potential of EVs, several challenges and limitations must be addressed. The isolation and characterization of EVs remain complex due to their heterogeneous nature and varying sizes [25]. Standardized protocols for EV isolation and characterization are crucial for reproducibility and reliability in research and clinical applications. Additionally, the mechanisms by which EVs exert their effects on target cells require further investigation to fully understand their immunomodulatory capabilities [26].

CONCLUSION

Extracellular vesicles represent a novel class of immunomodulatory agents with significant potential for the treatment of autoimmune and inflammatory diseases. Their ability to modulate immune responses, promote tissue repair, and serve as biomarkers highlights their versatility in therapeutic applications. As research progresses, a better understanding of the biogenesis, composition, and mechanisms of action of EVs will pave the way for innovative therapies that harness their immunomodulatory properties, offering new hope for patients with autoimmune and inflammatory conditions. The future exploration of EVs in clinical settings may lead to transformative advancements in the management of these diseases.

REFERENCES

1. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013 Feb 18;200(4):373-83. doi: 10.1083/jcb.201211138. PMID: 23420871; PMCID: PMC3575529.
2. Maas SLN, Breakefield XO, Weaver AM. Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends Cell Biol. 2017 Mar;27(3):172-188. doi: 10.1016/j.tcb.2016.11.003. Epub 2016 Dec 13. PMID: 27979573; PMCID: PMC5318253.
3. Latifkar A, Hur YH, Sanchez JC, Cerione RA, Antonyak MA. New insights into extracellular vesicle biogenesis and function. J Cell Sci. 2019 Jul 1;132(13):jcs222406. doi: 10.1242/jcs.222406. PMID: 31263077; PMCID: PMC6633391.
4. Sagini K, Costanzi E, Emiliani C, Buratta S, Urbanelli L. Extracellular Vesicles as Conveyors of Membrane-Derived Bioactive Lipids in Immune System. Int J Mol Sci. 2018 Apr 18;19(4):1227. doi: 10.3390/ijms19041227. PMID: 29670015; PMCID: PMC5979532.
5. Sagini K, Costanzi E, Emiliani C, Buratta S, Urbanelli L. Extracellular Vesicles as Conveyors of Membrane-Derived Bioactive Lipids in Immune System. Int J Mol Sci. 2018 Apr 18;19(4):1227. doi: 10.3390/ijms19041227. PMID: 29670015; PMCID: PMC5979532.
6. Hackel A, Vollmer S, Bruderek K, Lang S, Brandau S. Immunological priming of mesenchymal stromal/stem cells and their extracellular vesicles augments their therapeutic benefits in experimental graft-versus-host disease *via* engagement of PD-1 ligands. Front Immunol. 2023 Feb 16;14:1078551. doi: 10.3389/fimmu.2023.1078551. PMID: 36875112; PMCID: PMC9978482.
7. Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases. Cells. 2019 Dec 11;8(12):1605. doi: 10.3390/cells8121605. PMID: 31835680; PMCID: PMC6952783.
8. Das K, Paul S, Mukherjee T, Ghosh A, Sharma A, Shankar P, Gupta S, Keshava S, Parashar D. Beyond Macromolecules: Extracellular Vesicles as Regulators of Inflammatory Diseases. Cells. 2023 Jul 29;12(15):1963. doi: 10.3390/cells12151963. PMID: 37566042; PMCID: PMC10417494.
9. Chong SY, Lee CK, Huang C, Ou YH, Charles CJ, Richards AM, Neupane YR, Pavon MV, Zharkova O, Pastorin G, Wang JW. Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers. Int J Mol Sci. 2019 Jul 3;20(13):3272. doi: 10.3390/ijms20133272. PMID: 31277271; PMCID: PMC6650854.
10. Varderidou-Minasian S, Lorenowicz MJ. Mesenchymal stromal/stem cell-derived extracellular vesicles in tissue repair: challenges and opportunities. Theranostics. 2020 May 1;10(13):5979-5997. doi: 10.7150/thno.40122. PMID: 32483432; PMCID: PMC7254996.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

11. Latifkar A, Hur YH, Sanchez JC, Cerione RA, Antonyak MA. New insights into extracellular vesicle biogenesis and function. J Cell Sci. 2019 Jul 1;132(13):jcs222406. doi: 10.1242/jcs.222406. PMID: 31263077; PMCID: PMC6633391.
12. Clancy JW, Schmidtmann M, D'Souza-Schorey C. The ins and outs of microvesicles. FASEB Bioadv. 2021 Mar 4;3(6):399-406. doi: 10.1096/fba.2020-00127. PMID: 34124595; PMCID: PMC8171306.
13. Li G, Chen T, Dahlman J, Eniola-Adefeso L, Ghiran IC, Kurre P, Lam WA, Lang JK, Marbán E, Martín P, Momma S, Moos M, Nelson DJ, Raffai RL, Ren X, Sluijter JPG, Stott SL, Vunjak-Novakovic G, Walker ND, Wang Z, Witwer KW, Yang PC, Lundberg MS, Ochocinska MJ, Wong R, Zhou G, Chan SY, Das S, Sundd P. Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseases. J Extracell Vesicles. 2023 Feb;12(2):e12305. doi: 10.1002/jev2.12305. Erratum in: J Extracell Vesicles. 2023 Mar;12(3):e12314. doi: 10.1002/jev2.12314. PMID: 36775986; PMCID: PMC9923045.
14. Lindenbergh MFS, Koerhuis DGJ, Borg EGF, van 't Veld EM, Driedonks TAP, Wubbolts R, Stoorvogel W, Boes M. Bystander T-Cells Support Clonal T-Cell Activation by Controlling the Release of Dendritic Cell-Derived Immune-Stimulatory Extracellular Vesicles. Front Immunol. 2019 Mar 12; 10:448. doi: 10.3389/fimmu.2019.00448. PMID: 30915085; PMCID: PMC6423080.
15. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P, Grohmann U. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011 Jul 31;12(9):870-8. doi: 10.1038/ni.2077. PMID: 21804557.
16. Barnes BJ, Somerville CC. Modulating Cytokine Production via Select Packaging and Secretion from Extracellular Vesicles. Front Immunol. 2020 May 29; 11:1040. doi: 10.3389/fimmu.2020.01040. PMID: 32547552; PMCID: PMC7272603.
17. Hou JJ, Li WW, Wang XL, Ma AH, Qin YH. Efficacy of extracellular vesicles as a cell-free therapy in colitis: a systematic review and meta-analysis of animal studies. Front Pharmacol. 2023 Oct 26; 14:1260134. doi: 10.3389/fphar.2023.1260134. PMID: 37954844; PMCID: PMC10637393.
18. Lo Sicco C, Reverberi D, Balbi C, Ulivi V, Principi E, Pascucci L, Becherini P, Bosco MC, Varesio L, Franzin C, Pozzobon M, Cancedda R, Tasso R. Mesenchymal Stem Cell-Derived Extracellular Vesicles as Mediators of Anti-Inflammatory Effects: Endorsement of Macrophage Polarization. Stem Cells Transl Med. 2017 Mar;6(3):1018-1028. doi: 10.1002/sctm.16-0363. Epub 2017 Jan 31. PMID: 28186708; PMCID: PMC5442783.
19. Rojas C, Campos-Mora M, Cárcamo I, Villalón N, Elhusseiny A, Contreras-Kallens P, Refisch A, Gálvez-Jirón F, Emparán I, Montoya-Riveros A, Vernal R, Pino-Lagos K. T regulatory cells-derived extracellular vesicles and their contribution to the generation of immune tolerance. J Leukoc Biol. 2020 Sep;108(3):813-824. doi: 10.1002/JLB.3MR0420-533RR. Epub 2020 Jun 12. PMID: 32531824.
20. Fu L, Jin L, Yan L, Shi J, Wang H, Zhou B, Wu X. Comprehensive review of genetic association studies and meta-analysis on miRNA polymorphisms and rheumatoid arthritis and systemic lupus erythematosus susceptibility. Hum Immunol. 2016 Jan;77(1):1-6. doi: 10.1016/j.humimm.2014.09.002. Epub 2014 Sep 16. PMID: 25218914.
21. Walker S, Busatto S, Pham A, Tian M, Suh A, Carson K, Quintero A, Lafrence M, Malik H, Santana MX, Wolfram J. Extracellular vesicle-based drug delivery systems for cancer treatment. Theranostics. 2019 Oct 17;9(26):8001-8017. doi: 10.7150/thno.37097. PMID: 31754377; PMCID: PMC6857056.
22. Armstrong JPK, Stevens MM. Strategic design of extracellular vesicle drug delivery systems. Adv Drug Deliv Rev. 2018 May; 130:12-16. doi: 10.1016/j.addr.2018.06.017. Epub 2018 Jun 28. PMID: 29959959; PMCID: PMC6606438.
23. Shigemoto-Kuroda T, Oh JY, Kim DK, Jeong HJ, Park SY, Lee HJ, Park JW, Kim TW, An SY, Prockop DJ, Lee RH. MSC-derived Extracellular Vesicles Attenuate Immune Responses in Two Autoimmune Murine Models: Type 1 Diabetes and Uveoretinitis. Stem Cell Reports. 2017 May 9;8(5):1214-1225. doi: 10.1016/j.stemcr.2017.04.008. PMID: 28494937; PMCID: PMC5425726.
24. Casella G, Rasouli J, Boehm A, Zhang W, Xiao D, Ishikawa LLW, Thome R, Li X, Hwang D, Porazzi P, Molugu S, Tang HY, Zhang GX, Ciric B, Rostami A. Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice. SciTransl Med. 2020 Nov 4;12(568): eaba0599. doi: 10.1126/scitranslmed.aba0599. PMID: 33148622; PMCID: PMC7886371.
25. Gardiner C, Di Vizio D, Sahoo S, Théry C, Witwer KW, Wauben M, Hill AF. Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. J Extracell Vesicles. 2016 Oct 31; 5:32945. doi: 10.3402/jev.v5.32945. PMID: 27802845; PMCID: PMC5090131.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

26. Xie M, Xiong W, She Z, Wen Z, Abdirahman AS, Wan W, Wen C. Immunoregulatory Effects of Stem Cell-Derived Extracellular Vesicles on Immune Cells. Front Immunol. 2020 Feb 11; 11:13. doi: 10.3389/fimmu.2020.00013. PMID: 32117221; PMCID: PMC7026133.

CITE AS: Awafung Emmanuel Adie (2024). Extracellular Vesicles as Novel Immunomodulatory Agents: Potential for Autoimmune and Inflammatory Diseases. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY 5(3):33-37.
https://doi.org/10.59298/NIJPP/2024/5333370